NEW YORK (TheStreet) -- Valeant Pharmaceuticals and Allergan are higher on Monday thanks to Valeant reporting good earnings and saying it is considering raising its bid for Allergan. Jim Cramer, the co-manager of the Action Alerts PLUS portfolio, said he's "never seen a situation where there are so many winners."
On CNBC's "Cramer's Stop Trading" segment, he noted Valeant Pharmaceuticals beat revenue and earnings estimates. He said he's "not been a fan" of Valeant but admittted the company continues to deliver solid results for investors.
On CNBC's "Cramer's Stop Trading" segment, he noted Valeant Pharmaceuticals beat revenue and earnings estimates. He said he's "not been a fan" of Valeant but admittted the company continues to deliver solid results for investors.
Cramer
Aucun commentaire:
Enregistrer un commentaire